Non-Hodgkin lymphoma: oncogenic mechanisms and therapeutic target
| Lymphoma Subtype . | Pathways altered . | Targeted Agents . | Clinical trials . | Age of patients eligible (years) . |
|---|---|---|---|---|
| DLBCL | Programmed death-1 | Pembrolizumab | NCT02541565 | 18+ |
| CD79b | Polatuzumab vedotin | NCT01992653 | 60-80 | |
| Programmed death-1 plus BCR activation | Nivolumab plus ibrutinib | NCT02329847 | 18+ | |
| CD20 | Obinutuzmab | NCT02670317 | 18-60 | |
| BCL-2 | Venetoclax | NCT02055820 | 18+ | |
| NK cell activation | Lenalidomide | NCT00670358 | 18-120 | |
| CD30 | Brentuximab vedotin | NCT01925612 | 18+ | |
| GCB | BCL-2 translocation | |||
| EZH2 mutations | CUDC-907 | NCT01742988 | 18+ | |
| PTEN deletions | ||||
| nonGCB | NF-κB activation | Bortezomib | NCT01848132 | 18-70 |
| CARD11 mutations | ||||
| BCR mutations | Ibrutinib | NCT02219737 | 18+ | |
| MYD88 mutations | Ibrutinib | NCT02219737 | 18+ | |
| DHL | MYC aberrations | CUDC-907 | NCT02674750 | 18+ |
| PMLBCL | Programmed death-1 | Pembrolizumab | NCT02576990 | 18+ |
| NF-κB activation | ||||
| CD30 | Brentuximab vedotin | NCT02423291 | 18+ | |
| JAK2 mutations | Ruxolitinib | NCT01965119 | 19-80 | |
| REL amplifications | ||||
| ALCL | ||||
| ALK+ | CD30 | Brentuximab vedotin | NCT01777152 | 18+ |
| ALK fusion protein | Crizotinib | NCT01979536 | 0-21 | |
| ALK– | CD30 | Brentuximab vedotin | NCT01777152 | 18+ |
| Lymphoma Subtype . | Pathways altered . | Targeted Agents . | Clinical trials . | Age of patients eligible (years) . |
|---|---|---|---|---|
| DLBCL | Programmed death-1 | Pembrolizumab | NCT02541565 | 18+ |
| CD79b | Polatuzumab vedotin | NCT01992653 | 60-80 | |
| Programmed death-1 plus BCR activation | Nivolumab plus ibrutinib | NCT02329847 | 18+ | |
| CD20 | Obinutuzmab | NCT02670317 | 18-60 | |
| BCL-2 | Venetoclax | NCT02055820 | 18+ | |
| NK cell activation | Lenalidomide | NCT00670358 | 18-120 | |
| CD30 | Brentuximab vedotin | NCT01925612 | 18+ | |
| GCB | BCL-2 translocation | |||
| EZH2 mutations | CUDC-907 | NCT01742988 | 18+ | |
| PTEN deletions | ||||
| nonGCB | NF-κB activation | Bortezomib | NCT01848132 | 18-70 |
| CARD11 mutations | ||||
| BCR mutations | Ibrutinib | NCT02219737 | 18+ | |
| MYD88 mutations | Ibrutinib | NCT02219737 | 18+ | |
| DHL | MYC aberrations | CUDC-907 | NCT02674750 | 18+ |
| PMLBCL | Programmed death-1 | Pembrolizumab | NCT02576990 | 18+ |
| NF-κB activation | ||||
| CD30 | Brentuximab vedotin | NCT02423291 | 18+ | |
| JAK2 mutations | Ruxolitinib | NCT01965119 | 19-80 | |
| REL amplifications | ||||
| ALCL | ||||
| ALK+ | CD30 | Brentuximab vedotin | NCT01777152 | 18+ |
| ALK fusion protein | Crizotinib | NCT01979536 | 0-21 | |
| ALK– | CD30 | Brentuximab vedotin | NCT01777152 | 18+ |